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Abstract
Previously synthesized 2-(benzo[b]thiophene-3′-yl)-6,8,8-triethyldesmosdumotin B (1, TEDB-
TB) and 2-(naphth-1′-yl)-6,8,8-triethyldesmosdumotin B (2) showed potent activity against 
multiple human tumor cell lines, including a multidrug-resistant (MDR) subline, by targeting 
spindle formation and/or the microtubule network. Consequently, ester analogues of hydroxylated 
naphthyl substituted TEBDs (3–5) were prepared and evaluated for their effects on tumor cell 
proliferation and on tubulin assembly. Among all new compounds, compound 6, a 4′-
acetoxynaphthalen-1′-yl derivative, displayed the most potent antiproliferative activity (IC50 0.2–
5.7 μM). Selected analogues were confirmed to be tubulin assembly inhibitors in cell-free and cell-
based assays using MDR tumor cells. The new analogues partially inhibited colchicine binding to 
tubulin, suggesting their binding mode would be different from that of colchicine. This 
observation was supported by computational docking model analyses. Thus, the newly synthesized 
triethylated chromones with esterified naphthalene groups have good potential for development as 
a new class of mitotic inhibitors that target tubulin.
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1. Introduction
The structural diversity of natural products (NPs) has contributed significantly to past drug 
discovery. In their recent review, Newman and Cragg stated that NPs are still playing a 
dominant role in the current discovery of leads and development of drugs for the treatment 
of human diseases.1 The biosynthesis of NPs occurs efficiently via well-controlled reactions 
promoted by natural enzymes, while chemical syntheses of NPs are not always easy. 
Nonetheless, novel bioactive compounds that are biosynthetically not observed can be 
artificially produced as synthetic NP derivatives. Thus, the application of organic synthesis 
to core NP skeletons can supply richer structural variety to expand the possibility of potent 
drug leads. The chemical modification of lead natural products is also a useful strategy to 
improve the desired pharmacological activity and to reduce adverse clinical side effects. The 
differences in functional groups and their positions can affect various drug parameters, such 
as partition coefficient, electron density, structure conformation, bioavailability, and other 
pharmacokinetics factors involved in the interaction between ligand and cellular targets. We 
selected novel scaffolds that do not occur biosynthetically but can be converted to promising 
drug candidates, based on chemical modification of natural skeletons.
Aromatic ring systems are key scaffolds in medicinal chemistry, because their electron rich 
π systems and structurally rigid planar frameworks can often play a critical role in the 
interactions of ligands with their cellular targets. A phenyl group is the most common 
aromatic ring found in natural products. However, bicyclic aromatic systems, such as 
naphthalene, have expanded π orbitals, which can sometimes lead to dramatic changes in 
ligand–receptor interactions. It was reported previously that the biological profile of 
triethyldesmosdumotin B (TEDB) could be significantly changed based on the identity of 
the B-ring (Figure 1).2,3 When the pendant B-ring was a 6π-electron aromatic system, the 
TEDB analogue showed effective cytotoxicity only against p-glycoprotein (P-gp) 
overexpressing multi-drug resistant (MDR) cells, but no cytotoxicity against any 
chemosensitive tumor cell line.2–5 In contrast, compounds with a 10π-rather than 6π-
electron aromatic system, such as 2-(benzo[b]thiophene-3′-yl)-6,8,8-triethyldesmosdumotin 
B (1, TEDB-TB) and 2-(naphth-1′-yl)-6,8,8-triethyldesmosdumotin B (2), exhibited potent 
antiproliferative activity against multiple human cancer cell lines, including MDR tumor 
cells, acting via inhibition of tubulin polymerization, in part through the colchicine site 
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(CS).6 It was also found that hydroxylated benzothiophene analogues efficiently induced cell 
cycle arrest at the G2/M phase, with formation of immature multipolar spindles.7
To explore the biological potential of this compound class, we have continued the 
investigation of TEDB derivatives. A hydroxy group provides a polar surface on the 
naphthalene molecule, which has no topological polar surface area (tPSA) by itself. 
Hydroxy naphthalene derivatives 3–5, which were already in hand,7 could be easily 
esterified to produce various ester derivatives. Acyl group might contribute to H-bond 
interactions with the target protein or could provide a spacer element. Furthermore, the 
functional group differences might alter the biological profile, as we previously 
described.2–7
An ester group plays an important role in biological activity. A well-known instance is 
paclitaxel (PXL), an antitumor drug in clinical use. The ester side chain at position C-13, 
acetate at position C-4, and benzoate at position C-2 are essential for the antitubulin activity 
of PXL.8 Analogues without ester groups at the above mentioned positions or with 
simplified side chains at C-13 have dramatically reduced activity.
The antiproliferative activities of all new TEBD derivatives against several cancer cell lines, 
including an MDR cell line, were studied. Selected analogues were investigated for potential 
inhibitory effects on tubulin assembly with purified tubulin and for effects on cell cycle 
progression in human tumor cells.
2. Results and discussion
2.1. Chemistry
The hydroxylated analogues 3–5 were synthesized previously (Scheme 1).7 Esterifications 
of 3–5 were accomplished using the appropriate acyl chloride for 6–22. The structures and 
purities of all synthesized compounds were confirmed by 1H-NMR, high resolution MS, and 
HPLC analysis.
2.2. Biological evaluation and structure–activity relationship
2.2.1. Antiproliferative activity—Newly synthesized analogues 3–22 were tested for 
antiproliferative activity against eight human tumor cell lines, A549 (lung carcinoma), 
HCT-8 (colon adenocarcinoma), Hep G2 (hepatocellular carcinoma), PC-3 (prostate cancer), 
DU 145 (prostate cancer), SK-BR-3 (HER2-overexpressing breast cancer), KB (originally 
isolated from epidermoid carcinoma of the nasopharynx), and KB-subline KB-VIN showing 
MDR phenotype with overexpression of P-gp (Table 1). The antiproliferative effects of 
compounds were determined by the sulforhodamine B (SRB) assay, and IC50 values were 
calculated from at least three independent experiments with duplication. The 
antiproliferative activities of the compounds 2–5 are also shown for comparison. A cytotoxic 
P-gp substrate, PXL, was used as an experimental control. The selected analogues were also 
tested with purified tubulin for inhibitory effects on its assembly and on the binding of 
[3H]colchicine. The 50% effective concentration for inhibiting tubulin assembly (EC50-ITA) 
and percent inhibition of colchicine binding to tubulin (ICB) in the presence of tested 
compounds are also presented in Table 1. Combretastatin A-4 (CA-4), a colchicine-type 
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antitubulin agent, was used as a positive control for ITA (EC50 = 1.1 μM) and ICB (99% 
inhibition).
From the results with analogues 3 and 4, hydroxylation at the 4′-position (3) of 2′-naphthyl-
TEDB 2 effectively enhanced the cell growth inhibition in A549, Hep G2, KB and KB-VIN 
cell lines (IC50 0.9, 0.4, 0.7, and 0.5 μM, respectively), while hydroxylation at the 2′-
position (4) had less effect (IC50 1.2, 1.6, 1.0, and 1.0 μM, respectively). The latter potencies 
were closer to those of the parent 2.7 Although the antiproliferative activities of 3 and 4 were 
slightly different, their ITA and ICB potencies using a cell free system were comparable. In 
contrast, the 6′-hydroxy-1′-naphthyl-TEDB analogue (5) exhibited marginal 
antiproliferative potency.
Except 22, all tested compounds exhibited some antiproliferative activity (IC50 less than 20 
μM) against KB-VIN, a P-gp-overexpressing MDR tumor cell line. Therefore, these 
analogues are not P-gp substrates and can be effective against MDR tumors. Notably, the 
antiproliferative activity of cinnamoyl ester 13 against KB-VIN was eightfold greater than 
that against KB, the parent non-MDR tumor cell line.
Esterifications of naphthols 3 and 4 successfully increased or preserved the antiproliferative 
effects in most cases. Especially, acetate 6 exhibited significantly improved antiproliferative 
activity against all tested cell lines, except DU 145 and SK-BR-3. The observed IC50 values 
of 0.2 to 0.5 μM were better than those of the parent 3. Benzoate 12 and acetate 6 inhibited 
tumor cell growth with similar potency, but 12 was slightly less active than 6 against KB-
VIN. Interestingly, benzoate 12 and propionate 7 did not inhibit tubulin assembly as opposed 
to 3 and acetate 6, although all four compounds showed potent antiproliferative activity. 
Unlike other esters of naphthol 3, compounds 9–11 displayed impressive activity against DU 
145 and SK-BR-3. Among the ester analogues of 4, acetate 15 demonstrated slightly better 
activity than the parent alcohol 4. Other analogues showed similar antiproliferative activity, 
but benzoate 17 and cinnamate 18 did not inhibit tubulin assembly. All four ester analogues 
(19–22) of 6′-naphthol 5 showed no significant improvement in antiproliferative activity as 
compared with the parent compound.
Selected active compounds were tested for potential inhibition of tubulin assembly. 
Analogues 3, 4, 6, and 16 inhibited tubulin assembly and modestly inhibited colchicine 
binding, while CA-4 caused 98% inhibition (data not shown) at the inhibitor concentration 
used. This observation suggested that these compounds might target tubulin in a different 
manner from CS-binding agents.
2.2.2. Effects on cell cycle—Because induction of cell cycle arrest at G2/M is one of the 
typical effects of tubulin inhibitors on tumor cells, the effect of the newly synthesized 
compounds on cell cycle progression by using flow cytometry was investigated (Figure 2). 
Antimitotic natural products such as colchicine, VIN and PXL inhibit cell cycle progression 
at the G2/M phase in chemosensitive tumors. However, these three compounds are 
ineffective against MDR tumors overexpressing ABC transporter(s).7 The newly synthesized 
compounds suppressed MDR and chemosensitive cell growth at the same concentrations, we 
analyzed the cell cycle progression of KB-VIN cells treated with selected analogues, 
Nakagawa-Goto et al. Page 4
Bioorg Med Chem. Author manuscript; available in PMC 2017 November 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
including 7, 12 and 18, which showed little or no effects on the assembly of purified tubulin. 
As shown in Figure 2, except 13, all tested compounds induced cell cycle arrest at the G2/M 
phase within 24 h. Analogues 7, 12 and 18, which had tubulin assembly EC50 values > 20.0 
μM, also induced cell cycle arrest at G2/M, suggesting that these compounds may be 
activated in the cells or have a target other than tubulin. These results also suggest that the 
more selective antiproliferative effect of 13 against KB-VIN as compared with KB may not 
have been caused by an impact on the cell cycle, but may target a protein other than tubulin, 
such as a MDR-related protein responsible for cell growth. Further mechanism of action 
studies are required to elucidate a unique bioactivity of 13.
To study further the effects of the analogues on microtubules and spindle formations, as well 
as to determine their point of impact on the cell cycle, treated KB-VIN cells were labeled 
with antibodies against α-tubulin and serine 10-phosphorylated histone H3 (p-H3) as a 
mitotic chromosome condensation marker and with 4 ,6-diamidino-2-phenylindole (DAPI), 
which labels DNA (Figure 3). In the DMSO-treated control cells, p-H3-positive mitotic cells 
displayed normal bipolar spindle formation, and normal microtubule networks without p-H3 
labeling were present in interphase. In contrast, in cells treated with compounds 3, 4, 16 or 
18, abnormal multipolar spindles were often present in the chromosome-condensed p-H3-
positive mitotic cells, while disrupted microtubules were observed in interphase cells. Dose 
increases stimulated these microtubule defects, suggesting a dose-dependent manner of 
action. Multiple α-tubulin accumulated spots in p-H3-positive cells were obvious following 
treatment with 4 or 18, demonstrating that these analogues disrupt spindle formation and 
amplify the spindle poles at prometaphase. These observations support the flow cytometry 
results that showed induction of cell cycle arrest at G2/M. Based on these immunostaining 
studies, bipolar spindle formation was almost eliminated, confirming that the cells were 
arrested at prometaphase. Multipolar spindle formations were obvious in the mitotic cells, 
while undetectable in CA-4-treated cells. These phenotypes were clearly different from that 
of CA-4-treated cells, suggesting that our analogues exert a different mechanism of action 
than does CA-4.
Furthermore, analogue 18, which had an EC50 > 20.0 μM for inhibition of purified tubulin 
assembly, also showed the same phenotype as analogues 4 and 16. These results suggest that 
18 may be biologically activated in the cell-based assay to target tubulin to cause the arrest 
of cells at prometaphase with induction of multipolar spindles.
2.2.3 Induction of nuclear fragmentation—In the course of phenotypic analysis, we 
found that compounds 4 and 18 induced nuclear fragmentation (Figure 4, yellow arrows), 
while such fragmentation was undetectable in cells treated with 16 (Figure 3). Fragmented 
nuclei from treatment with 4 were negative against an antibody to p-H3, suggesting that the 
fragmentation was induced at interphase. In contrast, fragmented nuclei from 18 were 
stained with an antibody to p-H3 (blue arrows), suggesting that fragmentation was induced 
after the onset of chromosome condensation. As mentioned above, we believe that 18 is 
most likely biologically activated in the cells. This activation process could produce multiple 
forms of 18-related bioactive compounds, and one of these could show similar effects to 
those observed with 4. Unfortunately, it is still unclear whether the nuclear fragmentation 
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was a consequence of tubulin inhibitory effects, because nuclear fragmentation was not 
detected in cells treated with 16 or CA-4. Further mechanism of action studies are required 
to address this point and compounds 4 and 18 may have more than one target.
2.2.4. Docking models of compounds—The immunocytochemical evaluations 
described above demonstrated that the new analogues affected microtubule polymerization 
and especially induced dysfunction of bipolar spindle formation. These phenotypes are 
similar to but significantly different from those observed with CA-4. In fact, interphase 
microtubules as well as spindles and their poles were totally depolymerized by CA-4, while 
amplified spindle poles and immature multiple spindles were formed by treatment with 
synthetic analogues (Figure 3). Based on these observations, we predicted that our new 
analogues targeted the CS on tubulin, but in a different docking mode from that of 
colchicine. Previously, we reported a theoretical binding mode of TEDB-TB analogues 
docked into the CS through hydrogen bonds (H-bonds) formed with both α- and β-tubulins 
without interfering with colchicine binding.7 Thus, we employed computer modeling using 
the tubulin crystal structure (PDB ID: 1SAO) in the current study.
4′-Naphthol 3 and its acetate 6, which inhibited the assembly of purified tubulin, were 
computationally docked within the CS (Figure 5A). As we expected, the detailed docking 
model revealed that three oxygen atoms on the chromone skeletons of 3 and 6 formed H-
bonds with Asn101, Ser178, and Thr179 on α-tubulin (Figure 5B). Propionyl ester 7, which 
has only one additional carbon atom as compared with acetate 6, but had an EC50 > 20.0 μM 
in the purified tubulin assembly assay, could be similarly docked into the CS. However, it 
was conceivable that the propionyl side chain on the naphthalene ring had unfavorable steric 
interactions with Leu252 and Leu255 on β-tubulin, resulting in 7 being incapable of docking 
within the CS (dotted circle in Figure 5C). Distances of 5.33 and 4.44 Å were calculated 
between the terminal methyl group of the acetyl side chain of 6 with βLeu252 and βLeu255, 
respectively. In comparison, the terminal methyl group of the propionyl moiety of 7 was 
closer to βLeu252 and βLeu255, with calculated distances of 3.84 and 3.80 Å, respectively 
(Figure 5D). These observations could support the differing results in the tubulin assembly 
assay, in which 6 and 7 had EC50’s of 2.4 and > 20 μM, respectively (Table 1, ITA).
The docking studies on the 2′-ester analogues with the CS was also consistent with the 
distinctive bioactivities of the different analogues in the tubulin assembly assay. In the 
overlapped docking modes of 4 and CA-4, 4 formed three H-bonds with αAsn101, αSer178 
and αThr179, while CA-4 formed only one H-bond with αSer178 (Figures 6A, B). This 
difference could result in the apparently different impacts on tubulin assembly, as well as the 
different phenotypes observed in compound-treated cells at the onset of mitosis. The 
superimposition of docked 16 demonstrated that only one H-bond would be formed between 
the ester carbonyl group and αAsn101 (Figure 6C). No H-bonds were possible with 
αSer178 and αThr179, because the naphthyl ring directly faced these residues. In the 
predicted docking models of 16 and 17 in the CS, the benzoate phenyl ring of 17 was quite 
close to βAsn249 and βLys254, likely resulting in steric obstruction, while the propionyl 
side chain of 16 seemed to have adequate space near these two residues (Figure 6D). These 
results indicated that the docking of 17 into the CS would be improbable as compared with 
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16, supporting the results from the tubulin assembly assay, in which 16 had an EC50 of 2.3 
μM, while 17 had an EC50 > 20.0 μM. In addition, superimposition of 18 into the CS showed 
no H-bond formation, suggesting that 18 would be incapable of docking into the CS (Figure 
6E). These differences in the modeling study reflect the differences in the tubulin assembly 
assay, where 2′-naphthol 4 and propionate 16 inhibited tubulin assembly, while benzoate 17 
and cinnamate 18 yielded EC50 values > 20.0 μM.
The best-scored docking models of compounds 4, 16, 17, and 18 within the CS were 
analyzed for potential predictive utility with the tubulin assembly assay. These four 
compounds were selected because 4 and 16 were good inhibitors, while 17 and 18 had little 
if any inhibitory activity (see ITA values in Figure 7A). The binding ability of each ligand in 
the CS was evaluated by H-bond formation (Figures 5A–C and 6A–C). Furthermore, steric 
hindrance between the ligand and the tubulin amino acid residues was also considered as a 
critical binding factor (Figures 5D, 6D). The distances between the compound and the amino 
acid residues, especially βAsn249, βLys254, βThr314, and βAsn350, on β-tubulin in the CS 
are summarized in Figure 7B. No significant steric hindrance was anticipated for 4 and 16, 
with over 5Å distances from the amino acid residues. However, while the phenyl group on 
the benzoate of 17 has adequate distances from βThr314 (4.94 Å) as well as βAsn350 (5.32 
Å), the phenyl group on the cinnamate of 18 is quite close to βThr314 (3.11 Å) and 
βAsn350 (3.15 Å). Both the benzoate group of 17 as well as the naphthyl of 18 are close to 
βAsn249 (3.81 and 3.76 Å, respectively) and βLys254 (3.83 and 3.34 Å, respectively), 
which may obstruct docking. These analyses suggest that the additional phenyl group on the 
naphthalene might not bind to the CS due to the steric hindrance. This reasoning also 
concurs with the finding that 17 and 18 yielded EC50’s > 20.0 μM in the tubulin assembly 
assay. Thus, our docking models could be useful in the design of a new CS agent by 
calculating potential for H-bond formation and steric hindrance.
3. Conclusions
In summary, new ester analogues 5–22 from hydroxy TEDB-TBs 3–5 were synthesized, and 
their biological activities were evaluated. All ester analogues derived from 3 and 4, except 8, 
showed significant antiproliferative activity against multiple tumor cell lines, including the 
MDR line. Acetate, propionate, and benzoate analogues exhibited more potent activity than 
the parent compounds, 3 and 4. These cytotoxic analogues induced cell cycle arrest at the 
G2/M phase, and the arrest was at prometaphase by disrupting bipolar spindle formation. 
Amplification of spindle poles resulted in the formation of multipolar spindles observed in 
cells treated with the most potent compounds. This phenotype is different from that of other 
CS agents, such as CA-4, and characteristic of TEDB analogues. Computer-assisted docking 
modes of compound binding to the CS suggested that modified TEDB analogues and 
colchicine bind to the CS via different binding modes. We found that predicted H-bond 
formation and steric hindrance between compound and amino acid residues in the CS was 
consistent with the observed inhibitory effects on tubulin assembly. The contradictions 
between cell-free and cell-based antitubulin effects, such as found with compounds 7, 12, 
and 18, can possibly be explained by the biological activation of these analogues in the 
cancer cells. These analogues may have potential for the development of anticancer 
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prodrugs. Thus, our docking models combined with bioactivity results may be useful for the 
design of a novel prodrug targeting tubulin.
4. Experimental sections
4.1. Chemistry
4.1.1. General Experimental Procedures—All chemicals and solvents were used as 
purchased. All melting points were measured on a Fisher-Johns melting point apparatus 
without correction. 1H and 13C NMR spectra were recorded on a Varian Gemini 2000 (300 
MHz) or a Varian Inova (400 MHz, 600 MHz) NMR spectrometer with TMS as the internal 
standard. All chemical shifts are reported in ppm. NMR spectra were referenced to the 
residual solvent peak, chemical shifts δ in ppm, apparent scalar coupling constants J in Hz. 
Mass spectroscopic data were obtained on a Shimadzu LCMS-IT-TOF instrument or 
JMS-700 MStation (FAB). Analytical thin-layer chromatography (TLC) was carried out on 
Merck precoated aluminum silica gel sheets (Kieselgel 60 F-254). Teledyne Isco Combiflash 
system was used for flash chromatography. All target compounds were characterized and 
determined as at least >95% pure by 1H-NMR, HRMS, and analytical HPLC.
4.1.2. General Synthetic Procedures for Esterification—To a solution of hydroxy 
TEDB analogues (3–5) in CH2Cl2, Et3N (2.0 equiv. mol) and the related acyl chloride (1.1 
equiv. mol) were added at 0 ºC. The mixture was stirred at 0 ºC for 1.5 h. The reaction 
mixture was quenched with saturated aq. NH4Cl and extracted with CH2Cl2. The extract was 
washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified 
by silica gel chromatography with EtOAc–hexane as eluent to afford the related esters 6–22.
4.1.2.1. 4′-Acetoxynaphthalen-1′-yl-TEDB (6): 1H NMR (400 MHz, CDCl3) δ 13.00 
(1H, s, chelated-OH), 8.08–8.01 (1H, m, naphthalene-H), 7.98–7.91 (1H, m, naphthalene-
H), 7.69 (1H, d, J = 7.7 Hz, 2′-H), 7.73–7.69 (2H, m, naphthalene-H), 7.40 (1H, d, J = 7.7 
Hz, 3′-H), 6.80 (1H, s, 3-H), 2.53 (3H, s), 2.53–2.43 (2H, m), 2.24–2.14 (2H, m), 1.96–1.84 
(2H, m), 1.06 (3H, t, J = 7.3 Hz), 0.73 (6H, t, J = 7.3 Hz). HRMS m/z 447.1791 [M+H]+ 
(calcd for C27H26O6, 447.1802).
4.1.2.2. 4′-Propionyloxynaphthalen-1′-yl-TEDB (7): 1H NMR (600MHz, CDCl3) δ 
13.02 (1H, s, chelated-OH), 8.06–8.03 (1H, m, naphthalene-H), 7.96–7.93 (1H, m, 
naphthalene-H), 7.69 (1H, d, J = 8.0 Hz, 2′-H), 7.67–7.61 (2H, m, naphthalene-H), 7.41 
(1H, d, J = 8.0 Hz, 3′-H), 6.81 (1H, s, 3-H), 2.84 (2H, q, J = 7.4 Hz), 2.49 (2H, q, J = 7.4 
Hz), 2.23–2.16 (2H, m), 1.93–1.86 (2H, m), 1.41 (3H, t, J = 7.4 Hz), 1.06 (3H, t, J = 7.4 Hz), 
0.72 (6H, t, J = 7.4 Hz). HRMS m/z 461.1964 [M+H]+ (calcd for C28H28O6, 461.1959).
4.1.2.3. 4′-Isovaleryloxynaphthalen-1′-yl-TEDB (8): 1H NMR (600 MHz, CDCl3) δ 
13.01 (1H, s, chelated-OH), 8.08–8.03 (1H, m, naphthalene-H), 7.97–7.92 (1H, m, 
naphthalene-H), 7.68 (1H, d, J = 7.9 Hz, 2′-H), 7.67–7.61 (2H, m, naphthalene-H), 7.40 
(1H, d, J = 7.9 Hz, 3′-H), 6.80 (1H, s, 3-H), 2.68 (2H, d, J = 7.1 Hz), 2.48 (2H, q, J = 7.4 
Hz), 2.43–2.32 (1H, m), 2.24–2.13 (2H, m), 1.94–1.84 (2H, m), 1.15 (6H, d, J =6.6 Hz), 
1.06 (3H, t, J = 7.4 Hz), 0.72 (6H, t, J = 7.4 Hz). HRMS m/z 489.2289 [M+H]+ (calcd for 
C30H32O6, 489.2272).
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4.1.2.4. 4′-Butyryloxynaphthalen-1′-yl-TEDB (9): 1H NMR (300 MHz, CDCl3) δ 13.01 
(s, 1H, chelated-OH), 8.08–8.02 (1H, m, naphthalene-H), 7.98–7.92 (1H, m, naphthalene-
H), 7.69 (1H, d, J = 8.0 Hz, 2′-H), 7.68–7.61 (2H, m, naphthalene-H), 7.40 (1H, d, J = 8.0 
Hz, 3′-H), 6.80 (1H, s, 3-H), 2.78 (2H, t, J = 7.3 Hz), 2.49 (2H, q, J = 7.4 Hz), 2.24–2.13 
(2H, m), 1.99–1.84 (4H, m), 1.14 (3H, t, J = 7.3 Hz), 1.06 (3H, t, J = 7.4 Hz), 0.72 (6H, t, J = 
7.4 Hz). HRMS m/z 475.2121 [M+H]+ (calcd for C29H30O6).
4.1.2.5. 4′-Benzyloxynaphthalen-1′-yl-TEDB (10): 1H NMR (300 MHz, CDCl3) δ 13.00 
(1H, s, chelated-OH), 7.91 (1H, d, J = 8.4 Hz, Ph-H), 7.76 (1H, d, J = 8.4 Hz, Ph-H), 7.66 
(1H, d, J = 7.8 Hz, 2′-H), 7.60 (1H, dd, J = 7.8 and 7.0 Hz, Ar-H), 7.54 (1H, d, J = 7.8 Hz, 
3′-H), 7.52–7.48 (2H, m, naphthalene-H), 7.44 (2H, dd,J = 7.8 and 7.0 Hz, Ar-H), 7.42–7.35 
(2H, m, Ar-H), 6.78 (1H, s, 3-H), 4.07 (2H, s, -CH2Ph), 2.48 (2H, q, J = 7.4 Hz), 2.24–2.12 
(2H, m), 1.94–1.82 (2H, m), 1.06 (3H, t, J = 7.4 Hz), 0.71 (6H, t, J = 7.4 Hz). HRFABMS 
m/z 523.2128 [M+H]+ (calcd for C33H30O6, 523.2121).
4.1.2.6. 4′-Phenylpropanoyloxynaphthalen-1′-yl-TEDB (11): 1H NMR (300 MHz, 
CDCl3) δ 13.00 (1H, s, chelated-OH), 7.91 (1H, d, J = 8.2 Hz, Ar-H), 7.70 (1H, d, J = 8.4 
Hz, Ar-H), 7.65 (1H, d, J = 7.8 Hz, Ar-H), 7.61 (1H, dd, J = 8.4 and 7.0 Hz, Ar-H), 7.54 
(1H, dd, J = 8.2 and 7.0 Hz, Ar-H), 7.41–7.25 (6H, m, Ar-H), 6.79 (1H, s, 3-H), 3.24–3.09 
(4H, m), 2.48 (2H, q, J = 7.3 Hz), 2.24–2.11 (2H, m), 1.94–1.82 (2H, m), 1.06 (3H, t, J = 7.3 
Hz), 0.72 (6H, t, J = 7.3 Hz). HRMS m/z 537.2295 [M+H]+ (calcd for C34H32O6, 
537.2272).
4.1.2.7. 4′-Benzoyloxynaphthalen-1′-yl-TEDB (12): 1H NMR (400 MHz, CDCl3) δ 13.02 
(1H, s, chelated-OH), 8.35 (2H, d, J = 7.2 Hz, Ph-H), 8.15–8.09 (2H, m, Ph-H), 8.01–7.92 
(1H, m, naphthalene-H), 7.75 (1H, d, J = 7.9 Hz, 2′-H), 7.68–7.58 (2H, m, naphthalene-H), 
7.53 (1H, d, J = 7.9 Hz, 3′-H), 7.48 (2H, t, J = 7.9 Hz, naphthalene-H), 6.85 (1H, s, 3-H), 
2.49 (2H, q, J = 7.4 Hz), 2.26–2.15 (2H, m), 1.98–1.86 (2H, m), 1.07 (3H, t, J = 7.4 Hz), 
0.74 (6H, t, J = 7.4 Hz). HRMS m/z 509.1969 [M+H]+ (calcd for C32H28O6, 509.1959).
4.1.2.8. 4′-Cinnamoyloxynaphthalen-1′-yl-TEDB (13): 1H NMR (400 MHz, CDCl3) δ 
13.02 (1H, s, chelated-OH), 8.15–8.10 (1H, m, naphthalene-H), 8.04 (1H, d, J = 16.0 Hz), 
8.00–7.94 (1H, m, naphthalene-H), 7.3 (1H, d, J = 8.0 Hz, 2′-H), 7.70–7.63 (4H, m, Ph-H), 
7.52–7.46 (4H, m, Ph-H), 6.84 (1H, d, J = 16.0 Hz), 6.83 (1H, s, 3-H), 2.49 (2H, q, J = 7.4 
Hz), 2.26–2.14 (2H, m), 1.97–1.86 (2H, m), 1.07 (3H, t, J = 7.4 Hz), 0.74 (6H, t, J = 7.4 Hz). 
HRMS m/z 535.2118 [M+H]+ (calcd for C34H30O6, 535.2115).
4.1.2.9. 4′-Dimethylacryloxynaphthalen-1′-yl-TEDB (14): 1H NMR (400 MHz, CDCl3) 
δ 13.04 (1H, s, chelated-OH), 8.11–8.05 (1H, m, naphthalene-H), 7.98–7.91 (1H, m, 
naphthalene-H), 7.69 (1H, d, J = 7.8 Hz, 2′-H), 7.66–7.60 (2H, m, naphthalene-H), 7.41 
(1H, d, J = 7.8 Hz, 3′-H), 6.81 (1H, s, 3-H), 6.18–6.15 (1H, m), 2.48 (2H, q, J = 7.4 Hz), 
2.29 (3H, d, J = 1.2 Hz), 2.24–2.14 (2H, m), 2.09 (3H, d, J = 1.2 Hz), 1.95–1.84 (2H, m), 
1.06 (3H, t, J = 7.4 Hz), 0.72 (6H, t, J = 7.3 Hz). HRMS m/z [M+H]+ 487.2121 (calcd for 
C30H30O6, 487.2115).
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4.1.2.10. 2′-Acetoxynaphthalen-1′-yl-TEDB (15): 1H NMR (400 MHz, CDCl3) δ 12.93 
(1H, s, chelated-OH), 8.08 (1H, d, J = 9.1 Hz, naphthalene-H), 7.99–7.94 (1H, m, 
naphthalene-H), 7.61–4.56 (3H, m, naphthalene-H), 7.35 (1H, d, J = 9.1 Hz, naphthalene-H), 
6.68 (1H, s, 3-H), 2.48 (2H, q, J = 7.4 Hz), 2.26 (3H, s), 2.18–2.07 (2H, m), 1.88–1.76 (2H, 
m), 1.06 (3H, t, J = 7.4 Hz), 0.70 (6H, t, J = 7.3 Hz). HRMS m/z 447.1795 [M+H]+ (calcd 
for C27H26O6, 447.1802).
4.1.2.11. 2′-Propionyloxynaphthalen-1′-yl-TEDB (16): 1H NMR (300 MHz, CDCl3) δ 
12.93 (1H, s, chelated-OH), 8.08 (1H, d, J = 9.0 Hz, naphthalene-H), 7.99–7.94 (1H, m, 
naphthalene-H), 7.61–4.56 (3H, m,naphthalene-H), 7.34 (1H, d, J = 9.0 Hz, naphthalene-H), 
6.66 (1H, s, 3-H), 2.54 (2H, q, J = 7.6 Hz), 2.48 (2H, q, J = 7.4 Hz), 2.18–2.06 (2H, m), 
1.87–1.76 (2H, m), 1.20 (3H, t, J = 7.6 Hz3), 1.06 (3H, t, J = 7.4 Hz), 0.70 (6H, t, J = 7.4 
Hz). HRMS m/z 461.1952 [M+H]+ (calcd for C28H28O6, 461.1959).
4.1.2.12. 2′-Benzoyloxynaphthalen-1′-yl-TEDB (17): 1H NMR (400 MHz, CDCl3) δ 
12.86 (1H, s, chelated-OH), 8.16–8.01 (3H, m, Ar-H), 8.02–7.95 (1H, m, Ar-H), 7.69–7.42 
(7H, m, Ar-H), 6.72 (1H, s, 3-H), 2.42 (2H, q, J = 7.3 Hz), 2.12–2.00 (2H, m), 1.84–1.72 
(2H, m), 1.01 (t, 3H, J = 7.3 Hz), 0.51 (6H, t, J = 7.3 Hz). HRMS m/z 509.1976 [M+H]+ 
(calcd for C32H28O6, 509.1959).
4.1.2.13. 2′-Cinnamoyloxynaphthalen-1′-yl-TEDB (18): 1H NMR (400 MHz, CDCl3) δ 
12.92 (1H, s, chelated-OH), 8.11 (1H, d, J = 9.1 Hz, naphthalene-H), 8.00–7.94 (1H, m, 
naphthalene-H), 7.83 (1H, d, J = 16.0 Hz), 7.63–7.36 (9H, m, Ar-H), 6.55 (1H, d, J = 16.0 
Hz), 6.82 (1H, s, 3-H), 2.44 (2H, q, J = 7.4 Hz), 2.16–2.04 (2H, m), 1.89–1.79 (2H, m), 1.03 
(3H, t, J = 7.4 Hz), 0.66 (6H, t, J = 7.4 Hz). HRMS m/z 535.2138 [M+H]+ (calcd for 
C34H30O6, 535.2115).
4.1.2.14. 6′-Acetoxynaphthalen-2′-yl-TEDB (19): 1H NMR (400 MHz, CDCl3) δ 13.05 
(1H, s, chelated-OH), 8.31 (1H, br s, naphthalene-H), 8.01 (1H, d, J = 8.8 Hz, naphthalene-
H), 7.97 (1H, d, J = 8.8 Hz, naphthalene-H), 7.81 (1H, dd, J = 8.8 and 1.8 Hz, naphthalene-
H), 7.67 (1H, d, J = 2.2 Hz, naphthalene-H), 7.38 (1H, dd, J = 8.8 and 2.2 Hz, naphthalene-
H), 7.02 (1H, s, 3-H), 2.47 (2H, q, J = 7.4 Hz), 2.39 (3H, s), 2.37–2.25 (2H, m), 2.11–2.01 
(2H, m), 1.06 (3H, t, J = 7.4 Hz), 0.71 (6H, t, J = 7.4 Hz). HRMS m/z 447.1798 [M+H]+ 
(calcd for C27H26O6, 447.1802).
4.1.2.15. 6′-Propionyloxynaphthalen-2′-yl-TEDB (20): 1H NMR (300 MHz, CDCl3) δ 
13.06 (1H, s, chelated-OH), 8.31 (1H, br s, naphthalene-H), 8.01 (1H, d, J = 8.9 Hz, 
naphthalene-H), 7.96 (1H, d, J = 8.9 Hz, naphthalene-H), 7.81 (1H, dd, J = 8.9 and 1.9 Hz, 
naphthalene-H), 7.67 (1H, d, J = 2.3 Hz, naphthalene-H), 7.38 (1H, dd, J = 8.9 and 2.3 Hz, 
naphthalene-H), 7.02 (1H, s, 3-H), 2.69 (2H, q, J = 7.4 Hz3), 2.48 (2H, q, J = 7.4 Hz3), 2.36–
2.24 (2H, m), 2.12–2.00 (2H, m), 1.33 (3H, t, J = 7.4 Hz3), 1.06 (3H, t, J = 7.4 Hz3), 0.71 
(6H, t, J = 7.4 Hz). HRMS m/z 461.1952 [M+H]+ (calcd for C28H28O6, 461.1959).
4.1.2.16. 6′-Benzoyloxynaphthalen-2′-yl-TEDB (21): 1H NMR (400 MHz, CDCl3) δ 
13.06 (1H, s, chelated-OH), 8.35 (1H, br s, naphthalene-H), 8.26 (2H, d, J = 8.8 Hz, Ar-H), 
8.07 (1H, d, J = 8.8 Hz, Ar-H), 8.00 (1H, d, J = 8.6 Hz, Ar-H), 7.86–7.80 (2H, m, Ar-H), 
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7.74–7.66 (1H, m, Ar-H), 7.60–7.50 (3H, m, Ar-H), 7.04 (1H, s, 3-H), 2.49 (2H, q, J = 7.4 
Hz), 2.39–2.26 (2H, m), 2.14–2.02 (2H, m), 1.06 (3H, t, J = 7.3 Hz), 0.72 (6H, t, J = 7.3 Hz). 
HRMS m/z 509.1963 [M+H]+ (calcd for C32H28O6, 509.1959).
4.1.2.17. 6′-Cinnamoyloxynaphthalen-2′-yl-TEDB (22): 1H NMR (400 MHz, CDCl3) δ 
13.07 (1H, s, chelated-OH), 8.33 (1H, br s, naphthalene-H), 8.04 (2H, d, J = 8.8 Hz, Ar-H), 
8.00 (1H, d, J = 8.7 Hz, Ar-H), 7.95 (1H, d, J = 16.0 Hz, -COCH=CH-Ph), 7.82 (1H, dd, J = 
8.7 and 2.0 Hz, Ar-H), 7.67 (1H, d, J = 2.0 Hz, Ar-H), 7.66–7.60 (2H, m, Ar-H), 7.50–7.44 
(3H, m, Ar-H), 7.03 (1H, s, 3-H), 6.90 (1H, d, J = 16.0 Hz), 2.48 (2H, q, J = 7.4 Hz), 2.37–
2.26 (2H, m, 8-CH2CH3), 2.13–2.02 (2H, m), 1.06 (3H, t, J = 7.4 Hz), 0.71 (6H, t, J = 7.4 
Hz). HRMS m/z 535.2111 [M+H]+ (calcd for C34H30O6, 535.2115).
4.2. Biology
4.2.1. Antiproliferative Activity Assay—Antiprolierative activity of analogues was 
performed as described before.7 Briefly, all stock cell lines were grown in T-75 flasks at 
37 °C with 5% CO2 in air. Freshly trypsinized cell suspensions were seeded in 96-well 
microtiter plates at densities of 7,500–25,000 cells per well with compounds. Compounds 
were prepared in DMSO and diluted by culture medium. The highest concentration of 
DMSO in the cultures (0.1% v/v) was without effect on cell growth under the culture 
conditions used. After 72 h in culture with test compounds, cells were fixed in 10% 
trichloroacetic acid and then stained with 0.04% sulforhodamine B. The absorbance at 515 
nm was measured using a microplate reader (ELx800, BioTek) operated by Gen5 software 
(BioTek) after solubilizing the bound dye with 10 mM Tris base. The IC50 was calculated 
from at least three independent experiments performed with duplication. The following 
human tumor cell lines were used in the assay: A549 (lung carcinoma), Hep G2 
(hepatocellular carcinoma), HCT-8 (colon adenocarcinoma), KB (originally isolated from 
epidermoid carcinoma of the nasopharynx), and KB-VIN (vincristine-resistant KB subline 
showing MDR phenotype by overexpressing P-gp), PC-3 (androgen-insensitive prostate 
cancer), SK-BR-3 (ER-negative, progesterone receptor (PgR)-negative, HER2-
overexpressing breast cancer). All cell lines were obtained from the Lineberger 
Comprehensive Cancer Center (UNC-CH) or from ATCC (Manassas, VA), except KB-VIN, 
which was a generous gift from Professor Y.-C. Cheng (Yale University). Cells were 
cultured in RPMI-1640 medium supplemented with 2 mM L-glutamine and 25 mM HEPES 
(Mediatech), supplemented with 10% heat-inactivated fetal bovine serum (Hyclone), 100 
μg/mL streptomycin, and 100 IU penicillin. MDR stock cells (KB-VIN) were maintained in 
the presence of 100 nM vincristine.
4.2.2. Tubulin assays—Inhibitory effects of compounds against tubulin polymerization 
were evaluated as described previously, using purified bovine brain tubulin.9) Tubulin 
assembly was measured by turbidimetry at 350 nm. Assay mixtures contained 1.0 mg/mL 
(10 μM) tubulin and varying compound concentrations and were preincubated 15 min at 
30 °C without guanosine 5′-triphosphate (GTP). The samples were placed on ice, and 0.4 
mM GTP was added. Reaction mixtures were transferred to 0 °C cuvettes, and turbidity 
development was followed for 20 min at 30 °C following a rapid temperature jump. 
Compound concentrations as EC50 values that inhibited increase in turbidity by 50% relative 
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to a control sample were determined. Inhibition of the binding of [3H]colchicine to purified 
tubulin was measured as described previously.10) Tubulin (1.0 μM) was incubated with 5.0 
μM [3H]colchicine and 5.0 μM test compound at 37 °C for 10 min, when about 40–60% of 
maximum colchicine binding occurs in control samples.
4.2.3. Cell Cycle Analysis—Distribution of cells in the cell cycle was evaluated by 
measurement of cellular DNA content with propidium iodide (PI) (BD Biosciences) as 
described previously.7) Briefly, cells were seeded in a 12-well culture plate 24 h prior to 
treatment with compounds. Both KB and KB-VIN cells were treated with 1 and 10 μM 3, 4, 
6, 7, 12, 16, or 18, 10 and 40 μM 13, 0.2 μM CA-4, or vehicle (DMSO) as a control. Stained 
cells were analyzed by flow cytometry (BD FACSCalibur, BD Biosciences). Experiments 
were repeated a minimum of three times.
4.2.4. Immunofluorescence Staining—Immunostaining of KB-VIN was performed as 
described previously.7) Briefly, KB-VIN cells were grown on an 8-well chamber slide (Lab-
Tech) for 24 h prior to treatment with reagents. Cells were treated with reagent for 24 h. 
Concentrations of reagents were determined at their IC50 and/or effective concentration used 
for cell cycle analysis as follows: 0.2 μM combretastatin A-4, 10 μM for 3 and 4, 10 and 40 
μM for 16 and 18, and DMSO as a control. Cells were fixed in 4% paraformaldehyde in 
PBS, and permeabilized with 0.5% Triton X-100 in PBS. Fixed cells were labeled with 
mouse monoclonal antibody to α-tubulin (B5-1-2, Sigma) and rabbit IgG to Ser10-
phosphorylated histone H3 (p-H3) (#06-570, EMD Millipore), followed by FITC-conjugated 
antibody to mouse IgG (Sigma) and Alexa Fluor 549-conjugated antibody to rabbit IgG 
(Life Technologies). Nuclei were labeled with DAPI (Sigma). Fluorescence labeled cells 
were observed using a confocal microscope (Zeiss, LSM700) controlled by ZEN software 
(Zeiss). Confocal images were stacked and merged using ZEN (black edition) software. 
Final images were prepared using Photoshop CS6 (Adobe).
4.3. Computer Modeling
Three-dimensional (3D) structures of tubulin-ligand complexes were modeled by GOLD 5.1 
software11) with default settings. The 3D structure of human tubulin (TUBA1A and 
TUBB2B) used in this study was constructed from the Protein DataBank (PDB) entry (PDB 
ID: 1SA0).12) Missing hydrogen atoms in the crystal structure were computationally added 
by Hermes.13) The center of the active site was defined as the center of the ligand in 1SA0, 
and the active site radius was set to 10.0 Å. For the docking calculations, the quantum-
chemically optimized structures of ligands were used as initial structures. The structural 
optimizations of ligands were carried out by B3LYP/6-311+G(df,p) using Gaussian 09, 
Revision B.01.14)
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Figure 1. 
Structures of TEDB-TB Analogues
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Figure 2. Induction of cell cycle arrest at G2/M
KB-VIN cells were treated with the indicated compound for 24 h at the indicated 
concentrations. Harvested cells were subjected to flow cytometry after staining with 
propidium iodide (PI). DMSO and 0.2 μM of CA-4 were used as a negative control and an 
antitubulin agent arresting cells at G2/M, respectively.
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Figure 3. Effects of compounds on microtubule and spindle formation in KB-VIN cells in a dose 
dependent manner
KB-VIN cells were treated for 24 h with compound (3, 4, 16, or 18) at the indicated 
concentrations. CA-4 or DMSO was used as a positive control for a colchicine site 
antitubulin agent or negative control, respectively. Fixed cells were stained with antibodies 
to α-tubulin (green) and serine 10-phosphorylated histone H3 (p-H3, red) as a chromosome 
condensation marker, DAPI was used for DNA (blue). Stacked and merged confocal images 
are presented. Bar, 10 μm.
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Figure 4. Induction of nuclear fragmentation by 4 and 18
KB-VIN cells were treated for 24 h with 4 or 18 at 10 μM followed by fixing by PFA, 
staining with antibodies to α-tubulin (green) and chromosome condensation marker p-H3 
(red), and DAPI (blue) was used for DNA. Bar, 10 μm.
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Figure 5. Docking model of 4′-analogues in the colchicine site
(A) Docking model of 3 (green) and 6 (blue) in the colchicine site (CS) of the α-tubulin 
(white ribbon)/β-tubulin (red ribbon) crystal structure (PDB ID: 1SA0). (B) Superimposition 
of docked compounds 3 (green) and 6 (blue). (C) Superimposition of docked compounds 6 
(blue) and 7 (orange). (D) The distances (red dotted lines) between compounds and amino 
acid residues in β-tubulin.
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Figure 6. Docking model of 2′-analogues in the colchicine site
(A) Comparison of the docking mode of 4 (white) and CA-4 (orange) in the CS. (B & C) 
Superimposition of docked compounds 4 (gray skeleton with oxygen in red, hydrogen in 
white) (B), 16 (green), and 17 (pink) (C) in the CS of α-(gray ribbon) and β-tubulin (red 
ribbon) dimer. (D) The distances (red dotted lines) between compounds and amino acid 
residues in β-tubulin. (E) Superimposition of docked 18 (gray skeleton with oxygen in red, 
hydrogen in white) in the CS.
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Figure 7. 
Role of steric hindrance for docking to the colchicine site. (A) Possible steric hindrance 
between compounds 4, 16, 17, or 18 (gray skeleton with oxygen in red, hydrogen in white) 
and the CS. (B) The calculated distances between each compound (Comp.) and amino acid 
(aa) are denoted in Å.
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Scheme 1. Syntheses of New Analogues 6–22.
Reagents and conditions: a) Et3N, RCl [various acyl chlorides, such as acetyl chloride (R = 
CH3CO), propionyl chloride (R = CH3CH2CO), butyryl chloride (R = CH3CH2CH2CO), 
benzoyl chloride (R = PhCO), cinnamoyl chloride (R = PhCH=CHCO)]
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